Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Prompt antiretroviral therapy may help infants clear the HIV and achieve long-term remission

Prompt antiretroviral therapy may help infants clear the HIV and achieve long-term remission

Global inhibition of all Notch signals would not be safe after bone marrow transplantation

Global inhibition of all Notch signals would not be safe after bone marrow transplantation

PDL BioPharma fourth quarter total revenues increase to $86.0 million

PDL BioPharma fourth quarter total revenues increase to $86.0 million

Two antagonistic proteins help keep leukemia at bay

Two antagonistic proteins help keep leukemia at bay

Promyleocytic leukemia gene goes up significantly in post treatment of mTOR inhibitors

Promyleocytic leukemia gene goes up significantly in post treatment of mTOR inhibitors

Genetic variation in CD33 influences how AML patients' leukemic cell responds to GO

Genetic variation in CD33 influences how AML patients' leukemic cell responds to GO

Early lymphoid progenitors thrive in an osteoblastic niche: Study

Early lymphoid progenitors thrive in an osteoblastic niche: Study

Distinct bone marrow niches can nurture different types of blood stem cells

Distinct bone marrow niches can nurture different types of blood stem cells

Memorial Sloan-Kettering scientist wins Breakthrough Prize in Life Sciences

Memorial Sloan-Kettering scientist wins Breakthrough Prize in Life Sciences

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

TIR-199 shows promise in fighting renal cancer

TIR-199 shows promise in fighting renal cancer

Clonal evolution explains unpredictable leukemia disease course

Clonal evolution explains unpredictable leukemia disease course

Researchers show how gene mutations shift and evolve over time in chronic lymphocytic leukemia

Researchers show how gene mutations shift and evolve over time in chronic lymphocytic leukemia

LLS, The Myeloproliferative Neoplasm Research Foundation issue MF Challenge Grant

LLS, The Myeloproliferative Neoplasm Research Foundation issue MF Challenge Grant

FOXC2 vital to epithelial-mesenchymal transition in breast cancer

FOXC2 vital to epithelial-mesenchymal transition in breast cancer

Viewpoints: Obama prescription for Medicare is 'modest;' GOP doubts entitlement plan is serious

Viewpoints: Obama prescription for Medicare is 'modest;' GOP doubts entitlement plan is serious

Tousled-like kinases play a key role in suppression and activation of herpesviruses

Tousled-like kinases play a key role in suppression and activation of herpesviruses

Researchers investigate new avenue of treatment to help boost poor pancreatic cancer survival rates

Researchers investigate new avenue of treatment to help boost poor pancreatic cancer survival rates

RNF20 protein required for MLL-rearranged leukemia amplification

RNF20 protein required for MLL-rearranged leukemia amplification

Celgene receives FDA approval for POMALYST to treat multiple myeloma

Celgene receives FDA approval for POMALYST to treat multiple myeloma

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.